Sigma Ends Q4 With 1.8-Percent Organic Sales Growth; CEO Warns More Weakness Expected | GenomeWeb

Take away currency benefits of 4.8 percent, and a boost of 2.6 percent from acquisitions, and Sigma-Aldrich’s revenues grew 1.8 percent in the fourth quarter of FY 2004, the company reported this week.

“Market growth made our sales expectations a challenge in 2004 and I expect that it will continue to do so, if to a lesser degree, in 2005,” David Harvey, Sigma’s chairman and CEO, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.